Tadalafil Tablet, Film Coated
Product Images NDC 50090-6150

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 50090-6150). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500906150)

Packaging label for Tadalafil 20 mg tablets. The label indicates the product contains 30 tablets per container, with each film-coated tablet containing 20 mg of Tadalafil USP. Storage instructions specify to store at 77 degrees Fahrenheit. The label includes a lot number, a QR code, and distribution information for A-S Medication Solutions in Libertyville, Illinois.*

FDA Label Image

Figure (Tadalafil Figure1)

A set of four line graphs illustrating the difference in blood pressure measurements (mmHg) between Tadalafil and placebo over time in hours. The graphs show standing systolic, standing diastolic, supine systolic, and supine diastolic blood pressure, with time points up to 96 hours on the x-axis and the difference in blood pressure on the y-axis, including error bars for variability.*

FDA Label Image

Figure (Tadalafil Figure2)

Two line graphs display changes in systolic blood pressure (mmHg) over 24 hours post-dose. The top graph shows standing systolic blood pressure, while the bottom shows supine systolic blood pressure. Each graph compares Tadalafil 20 mg with doxazosin 8 mg (solid line) versus placebo with doxazosin 8 mg (dotted line). The x-axis indicates time in hours post-dose, and the y-axis shows blood pressure change in mmHg.*

FDA Label Image

Figure (Tadalafil Figure3)

A line graph depicting systolic blood pressure (mmHg) over 12 hours after administration of tadalafil or placebo combined with doxazosin at 08:00. Four groups are shown: 20 mg tadalafil at 08:00 and 20:00 with 8 mg doxazosin; and placebo at 08:00 and 20:00 with 8 mg doxazosin. The graph illustrates the blood pressure changes over time for each treatment combination.*

FDA Label Image

Figure (Tadalafil Figure4)

A line chart depicting plasma tadalafil concentration (µg/L) versus time (hours) for three dosing regimens: a single 20-mg dose, a single 5-mg dose, and once-daily 5-mg doses following 5 consecutive days of administration. The graph shows the concentration declining over time with error bars illustrating variability.*

FDA Label Image

Figure 5 (Tadalafil Figure5)

A line graph comparing the change from baseline in IPSS Total Score over 12 weeks of treatment between tadalafil 5 mg and placebo groups. The y-axis represents the change from baseline, and the x-axis shows treatment duration in weeks. The tadalafil group shows a greater decrease in score over time compared to placebo, with statistical significance indicated at 12 weeks.*

FDA Label Image

Figure 6 (Tadalafil Figure6)

A line graph showing change from baseline in IPSS total score over 12 weeks of treatment. Two lines compare tadalafil 5 mg and placebo groups, with tadalafil showing a greater reduction in IPSS score. Data points are at 0, 1, 4, 8, and 12 weeks, with a statistical significance indicator (p<0.01) at week 4.*

FDA Label Image

Figure 7 (Tadalafil Figure7)

This line graph compares mean changes from baseline over 26 weeks of therapy for groups receiving Tadalafil/Finasteride and Placebo/Finasteride. The vertical axis shows least-squares mean change values, and data points at weeks 0, 4, 12, and 26 illustrate treatment differences with statistical significance annotations.*

FDA Label Image

Figure 8 (Tadalafil Figure8)

A line graph comparing change from baseline in IPSS total score over a 12-week treatment period. It shows data for tadalafil 5 mg and placebo groups, with IPSS score change on the vertical axis and treatment duration in weeks on the horizontal axis. The tadalafil group demonstrates a greater decrease in IPSS score over time compared to placebo, with statistical significance noted at p<0.01.*

FDA Label Image

Chemical Structure (Tadalafil Structure)

Chemical structure diagram showing a complex molecule with fused rings including an indole group, a piperazine ring with a methyl group, and a dioxolane-substituted phenyl ring. The structure features multiple carbonyl groups and nitrogen atoms, indicative of a pharmaceutical compound.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.